[ad_1]
It was announced that the vaccine developed by Pfizer and BioNTech, which was advertised to be 90 percent effective against coronavirus, will be below market value. The agreement with the US stated that the dose of the vaccine would be 19.5 dollars (TL 159).
In an online event organized by the Financial Times newspaper, Ryan Richardson, head of strategy for the German company BionTech, said that the price of the vaccine, which was developed jointly with Pfizer from the US and has not yet received the legal approval, will reflect the financial risks of the private sector.
‘Prices may be different in certain parts of the world’
According to NTV, Richardson said: “We have tried to follow a balanced approach that recognizes that innovation requires capital and investment, so we plan to price our vaccine well below typical market rates that reflect our situation. However, Richardson declined to provide a clear figure for the price of the vaccine.
$ 19.5 per dose
According to DHA news, Pfizer signed a $ 1.95 billion settlement with the US government in July. This vaccine, which was administered in two doses, was reported to cost TL 159 per dose and TL 318 for two doses in the United States.
The European Commission, on the other hand, will discuss the details of its supply agreement with Pfizer and BioNTech tomorrow. Earlier this week, the bloc announced that a contract for 300 million doses was close to being signed without financial conditions.
On the other hand, Richardson reported that the two joint ventures are moving towards their goal of supplying 1.3 billion doses of vaccines to the world by the end of 2021.
[ad_2]
